Trial Profile

A Phase 2 study evaluating ME-344 plus Avastin in patients with relapsed colorectal cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 20 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Sep 2025 According to MEI Pharma media release, MEI Pharma has changed its name to Lite Strategy.
15 Jun 2023 According to a MEI Pharma media release, Mr. David Urso will provide an update on the pending merger and an overview of the combined company, which joins the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.
08 Sep 2022 According to a MEI Pharma media release, the company expect to initiate this trial in the first half of calendar year 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com